KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) FCF Margin (2017 - 2025)

Sarepta Therapeutics (SRPT) has 12 years of FCF Margin data on record, last reported at 37.56% in Q2 2025.

  • For Q2 2025, FCF Margin rose 4151.0% year-over-year to 37.56%; the TTM value through Dec 2025 reached 42.52%, down 131.0%, while the annual FY2024 figure was 300.6%, 25419.0% down from the prior year.
  • FCF Margin reached 37.56% in Q2 2025 per SRPT's latest filing, up from 559.9% in the prior quarter.
  • Across five years, FCF Margin topped out at 37.56% in Q2 2025 and bottomed at 641.83% in Q3 2023.
  • Average FCF Margin over 5 years is 122.14%, with a median of 57.9% recorded in 2023.
  • Peak YoY movement for FCF Margin: plummeted -70556bps in 2021, then surged 63195bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 28.16% in 2021, then plummeted by -111bps to 59.32% in 2022, then soared by 73bps to 15.9% in 2023, then surged by 67bps to 5.21% in 2024, then surged by 821bps to 37.56% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 37.56% in Q2 2025, 559.9% in Q1 2025, and 5.21% in Q4 2024.